search
Back to results

Social Forces to Improve Statin Adherence (Study B)

Primary Purpose

Medication Adherence, High Blood Pressure, Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Comparison to peers
Adherence feedback
Electronic pill bottle
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Medication Adherence focused on measuring Medication Adherence, High Blood Pressure, Diabetes, Statins

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The subject is Humana insured
  • The subject is an English speaking adult
  • Age range ≥18 years
  • The subject has diagnosis with diabetes for ≥12 months
  • The subject has an MPR <70% to a statin medication
  • Subjects denies side-effects to their statin medication

Exclusion Criteria:

  • The subject is <18 years old
  • The subject is considered part of a vulnerable population (is a prisoner, a cognitively impaired person, or a pregnant woman)
  • On statin combination medication
  • The subject does not identify an individual who agrees to serve as their MAP
  • The subject reports a clinically important side effect to the statin medication or active liver disease

Sites / Locations

  • University of Pennsylvania

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Other

Arm Label

Weekly Adherence Report

Weekly Adherence Peer-Comparison Report

Usual Care

Arm Description

Adherence report to subject every 7 days.

Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.

Usual care with GlowCap.

Outcomes

Primary Outcome Measures

Statin Adherence
The primary outcome will be the percent of statin doses taken during the study as measured by the GlowCaps.

Secondary Outcome Measures

Morisky Medication Adherence Scale (MMAS)
The secondary outcome will be subjects' self-reports medication adherence. Morisky et al. developed this 8-item MMAS (MMAS-8) in 2008. The first seven items are Yes/No responses while the last item is a 5-point Likert response. The scoring scheme is: "Yes" = 0 and "No" = 1 (and "0" = 0 and "1-4" = 1 for Likert question). The items are summed to give a range of scores from 0 to 8. Respondents' summed score get grouped as follows: "0" = High Adherence; "1-2" = Medium Adherence; "3-8" = Low Adherence.

Full Information

First Posted
December 17, 2013
Last Updated
July 11, 2017
Sponsor
University of Pennsylvania
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02148523
Brief Title
Social Forces to Improve Statin Adherence (Study B)
Official Title
Using Social Comparison To Improve Medication Adherence In Statin Users With Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To assess the effectiveness of social comparison in improving the outcome of statin adherence versus usual care as measured by an electronic pill bottle. Subjects receiving weekly reports with their adherence and information about their place in the distribution of their peers will have the highest statin adherence of any arm, as measured by electronic pill bottle.
Detailed Description
We propose to complete a randomized controlled trial (RCT) of 201 subjects with medication treated diabetes and evidence of poor adherence to a statin medication (<70% medication possession ratio (MPR) determined through pharmacy records; no combination meds). Study subjects will use GlowCaps to store their statin medication. Arm 1 will receive weekly feedback containing general information about the subject's adherence (i.e., reminding the subject how many days that week he or she took the medication). Arm 2 will be provided the same weekly feedback and the information of whether his or her adherence is above or below the average adherence in their arm, along with a message of encouragement tailored to their place in the arm distribution. Subjects with perfect adherence will receive: "You took your pill every day for the last 7 days. Great job! Keep it up" with their weekly adherence report. Subjects with less than perfect adherence and adherence rate in the top 50% of the arm will receive: "You took your pill for ** days out of the last 7 days. Your medication adherence was as good or better than half of people in this study. Taking your pill every day would improve your health even more" with their weekly adherence report. Subjects with less than perfect adherence and adherence rate in the bottom 50% of the arm will receive: "You took your pill for ** days out of the last 7 days. Your medication adherence was in the bottom half of the people in this study. If you took your pill more often, you could be in the top half of people in the study" with their weekly adherence report. Adherence records will be displayed on each subject's Way to Health (WTH) account in all arms. Arm 3 will be the usual care control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Medication Adherence, High Blood Pressure, Diabetes
Keywords
Medication Adherence, High Blood Pressure, Diabetes, Statins

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
201 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Weekly Adherence Report
Arm Type
Experimental
Arm Description
Adherence report to subject every 7 days.
Arm Title
Weekly Adherence Peer-Comparison Report
Arm Type
Experimental
Arm Description
Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
Arm Title
Usual Care
Arm Type
Other
Arm Description
Usual care with GlowCap.
Intervention Type
Behavioral
Intervention Name(s)
Comparison to peers
Intervention Type
Behavioral
Intervention Name(s)
Adherence feedback
Intervention Type
Device
Intervention Name(s)
Electronic pill bottle
Other Intervention Name(s)
Vitality GlowCap
Intervention Description
This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Primary Outcome Measure Information:
Title
Statin Adherence
Description
The primary outcome will be the percent of statin doses taken during the study as measured by the GlowCaps.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Morisky Medication Adherence Scale (MMAS)
Description
The secondary outcome will be subjects' self-reports medication adherence. Morisky et al. developed this 8-item MMAS (MMAS-8) in 2008. The first seven items are Yes/No responses while the last item is a 5-point Likert response. The scoring scheme is: "Yes" = 0 and "No" = 1 (and "0" = 0 and "1-4" = 1 for Likert question). The items are summed to give a range of scores from 0 to 8. Respondents' summed score get grouped as follows: "0" = High Adherence; "1-2" = Medium Adherence; "3-8" = Low Adherence.
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject is Humana insured The subject is an English speaking adult Age range ≥18 years The subject has diagnosis with diabetes for ≥12 months The subject has an MPR <70% to a statin medication Subjects denies side-effects to their statin medication Exclusion Criteria: The subject is <18 years old The subject is considered part of a vulnerable population (is a prisoner, a cognitively impaired person, or a pregnant woman) On statin combination medication The subject does not identify an individual who agrees to serve as their MAP The subject reports a clinically important side effect to the statin medication or active liver disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter P Reese, MD, MSCE
Organizational Affiliation
UPenn, PSOM
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Judd B Kessler, PhD
Organizational Affiliation
UPenn, Wharton
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kevin Volpp, MD, PhD
Organizational Affiliation
UPenn, PSOM
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Social Forces to Improve Statin Adherence (Study B)

We'll reach out to this number within 24 hrs